z-logo
Premium
The Effects of Age and Gender on the Single Dose Pharmacokinetics of Avitriptan Administered to Healthy Volunteers
Author(s) -
Marathe Punit H.,
Greene Douglas S.,
Kollia Georgia D.,
Barbhaiya Rashmi H.
Publication year - 1997
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1997.tb04268.x
Subject(s) - pharmacokinetics , urine , medicine , plasma concentration , area under the curve , desmethyl , time to peak , endocrinology , metabolite , pharmacology
The effects of age and gender on the single dose pharmacokinetics of avitriptan and its three metabolites were assessed in 15 young men, 15 young women, 15 elderly men and 15 elderly women. Avitriptan was administered as a 150‐mg capsule after a 10‐hour fast and serial plasma and urine samples were collected up to 36 hours after the dose. Plasma samples were analyzed for avitriptan and its metabolites, N‐desmethyl avitriptan (ND048), O‐desmethyl avitriptan (OD048), and methoxypyrimidinyl piperazine (MPP). Urine samples were analyzed for only avitriptan and MPP. Avitriptan was well tolerated in all four groups. The drug was rapidly absorbed with a median time to maximum plasma concentration (t max ) between 0.5 and 1.5 hours. No significant gender‐related differences were found in the maximum plasma concentration (C max ) and area under the concentration—time curve extrapolated to infinity (AUC 0‐∞ ) of avitriptan. Renal clearance of avitriptan was significantly smaller in young women compared with young men, but this is clinically not relevant because only 2% to 3% of the total dose is excreted unchanged. Compared with the young volunteers, mean C max was approximately 50% higher in the elderly but there was no difference in the AUC 0‐∞ between the 2 age groups. Plasma concentrations of ND048, OD048, and MPP were each 50 to 100 fold lower than those of avitriptan. Hence some age‐ and gender‐related differences found in the pharmacokinetics of avitriptan metabolites are probably not relevant in the assessment of overall safety and efficacy of avitriptan. Based on the pharmacokinetics and tolerability, no age or gender‐related dose adjustment is necessary for avitriptan . J Clin Pharmacol 1997;37:937–945.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here